Bardzo tanie apteki z dostawą w całej Polsce kupic cialis i ogromny wybór pigułek.

Microsoft word - 1383toc

ANTIDEPRESSANTS
MCP-1383
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY &
Are Antidepressants Totally Safe? A Moot but PRODUCT DEFINITIONS
Manufacturers Vociferous in their Protests.II-13 No Satisfactory Answers Yet – The Wait Grows Longer.II-13 II. EXECUTIVE SUMMARY
Global Antidepressants Market: Drug Regulation for Kids in Britain and the United States .II-13 1. Industry
Overview . II-1
3. Depression: A Mental Review . II-14
Industry Dynamics and Changing Scenario. II-2 Intense Competition in the Antidepressants Marketplace. II-2 Global Antidepressants Market (2004): Major Products Types of Depression and Related Disorders .II-15 Major Depressive Disorders (Major Depression).II-15 Table 1: Leading Brands in the Global Antidepressants Dysthymic Disorder (Minor Depression).II-15 Market (2001 & 2002): Sales in US$ Million for Seroxat/Paxil, Zoloft, Effexor, Cipramil/ Celexa, Wellbutrin, Prozac, Remeron, Fluoxetine Par, Serzone, and Fluoxetine Barr (include Premenstrual Dysphoric Disorder (PMDD) .II-16 corresponding Graphs/Chart) . II-4 Table 2: Leading Drugs in the Global Antidepressants Market (2003): Sales in US$ Million for Seroxat, Zoloft, Effexor, Cipramil/ Celexa, Wellbutrin, Cipralex/ Lexapro, Prozac, and Remeron (include corresponding Graphs/Chart) .II-5 Options Available in Depression Treatment .II-17 SSRI/SNRI Brands in the Global Antidepressants Market Psychotherapy or Psychiatric Consultation.II-17 (2002-2006): Sales in US$ Million by Geographic Combination of Psychotherapy and Pharmacotherapy.II-17 SSRIs Garnering Major Share of the Market. II-7 Table 3: Leading Brands in the Global SSRI Antidepressants How Can Depression Treatment become More Market (2003): Percentage Breakdown of Value Sales for Zoloft, Paxil and Paxil CR, Generic Fluoxetine, Celexa, Global Antidepressants Market: Favorable Drugs Lexapro, Prozac, Prozac Weekly, and Others (include corresponding Graphs/Chart) .II-7 Global Antidepressants Market: Unfavorable Emerging Antidepressant Classes Pose Threat to SSRI. II-8 Treatment-Resistant Depression (TRD) .II-19 2. Market Trends & Issues . II-9
New Drugs Making Way into the Market . II-9 Prozac Patent Expiry Opens Door for Generic Versions . II-9 Generic Antidepressants to Hit Market Soon . II-9 Table 4: Global Antidepressants Market (2004): Percentage Breakdown of Prevalence Rate by Disorder Type – Westerners Fight Depression Blues; Americans Depression, Anxiety, Obsessive Compulsive Disorder, Sleep Disorder, Panic Disorder, Phobias, and Others Antidepressants High in Demand but Fail to Satisfy (include corresponding Graphs/Chart) .II-20 No One is Immune: Not Even Animals!. II-11 Patent Expiry Disturbs Antidepressants Producers. II-11 Men Vs Women – Who is More Depression Prone? .II-21 Unlicensed Antidepressants Pose Danger to Depression and Smoking – Interlinked to One Another .II-22 Global Antidepressants Market (2003): Regulations 4. Product
Analysis . II-23
Governing Select Antidepressants Use in Children . II-12 What are Antidepressants? A Clear Understanding.II-23 Growing Safety Concerns – Antidepressants Under Fire . II-12 Global Antidepressants Market (2004): Select Brands ANTIDEPRESSANTS - A GLOBAL STRATEGIC BUSINESS REPORT 01/06 This Report Is Protected With Digital Watermarks. Copyrights per US & ICC protocols. This Document May Not Be Printed, Copied or Distributed Outside Your Organization in Any Form Without Our Express Written Permission ANTIDEPRESSANTS
MCP-1383
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
Adverse Effects of Antidepressants and their Select Antidepressants and their Applications . II-24 Tricyclic Antidepressants (TCAs) . II-25 Global Antidepressants Market: TCA Brands and Dosage Types - Starting Dosage and Normal Dosage.II-25 Global Antidepressants Market: TCAs and their Monamine Oxidase Inhibitors (MAOIs) . II-26 Side Effects Associated with Overdose .II-38 Global Antidepressants Market: MAOI Brands and Dosage Types – Starting Dosage and Normal Dosage .II-26 Table 5: Global Antidepressants Market: Percentage Side Effects of Different MAOIs – Tranylcypromine; Breakdown of Volume Drug Consumption by Disorder Type – Depression, Generalized Anxiety Disorder, Post Traumatic Selective Serotonin Reuptake Inhibitors (SSRIs). II-27 Stress Disorder, Panic Disorder and Others (include Global Antidepressants Market: SSRIs Brands and Related corresponding Graphs/Chart) .II-39 Do Antidepressants Treat Depression Completely?.II-40 Global Antidepressants Market: Withdrawal Symptoms Global Antidepressants Market: Different SSRI Antidepressants Used for Treatment of Panic Global Antidepressants Market: SSRIs’ Off-Label A Note of Caution for Panic Patients Using Antidepressants Used for Treatment of Anxiety 5HT2 Receptor Antagonist Properties. II-32 Antidepressants: Causes For and Against.II-45 Antidepressants Effective in Curing Premenstrual Antidepressants Offer Solution for Itching and Drugs and Dosage Types - Starting Dosage Antidepressants Offer Hope for Autistic Children.II-46 Antidepressants Minimize Hot Flushes and Antidepressants’ Positive Effect on the Brain .II-47 Global Antidepressants Market: Major Drugs by Longer Duration Antidepressants Treatment Class – SSRI, SNRI, MAOI, and NaSSA. II-34 Antidepressants - A New Option for Sleep Apnea .II-47 5. Antidepressants: An In-Depth Analysis . II-35
SSRI Antidepressants May Prove Helpful in Antidepressants, a Mere Accidental Discovery. II-35 Limited Choices and High Risk Rates . II-35 Lesser Fear of Breast Cancer with Antidepressants.II-48 Better Alternatives and Wider Choice – The New Mantra II-35 Antidepressants for Reducing Chronic Back Pain .II-48 Global Antidepressants Market: Launch of Drug Types – TCAs, MAOI, SSRI, and New Generation Variants Greater Heart at Risk with Antidepressants.II-48 by Original Version, Secondary Version, Antidepressants Dissipates Sexual Drive.II-49 Hip Fractures Troubles Aged Patients .II-49 ANTIDEPRESSANTS - A GLOBAL STRATEGIC BUSINESS REPORT 01/06 This Report Is Protected With Digital Watermarks. Copyrights per US & ICC protocols. This Document May Not Be Printed, Copied or Distributed Outside Your Organization in Any Form Without Our Express Written Permission ANTIDEPRESSANTS
MCP-1383
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
Antidepressants can be a Deadly Prescription Table 7: World 10-Year Perspective for Antidepressants by Geographic Region – Percentage Breakdown of Dental Problems with Antidepressants. II-50 Dollar Sales for USA, Canada, Japan, Europe, Facts/Myths About Antidepressants. II-50 Asia-Pacific (excluding Japan), and Latin America Are Pregnant Women at Risk from Antidepressants? . II-50 Markets for Years 2000, 2005 & 2010 (include Is Breast Feeding Safe While on Antidepressants?. II-51 corresponding Graphs/Chart) .II-64 Homeopathic Treatment Versus Antidepressants Recent Findings on Antidepressants . II-52 III. MARKET
6. Technological
Developments . II-53
Monitoring Technology Foresees Antidepressants 1. The United States . III-1
Vagus Nerve Stimulation - Device for Treating Global Antidepressants Market: FDA Approvals Antidepressants Usage in the United States .III-1 US Antidepressants Market: Drug Usage.III-2 7. Product
Introductions/Innovations. II-54
GlaxoSmithKline Re-Introduces Paxil CR in US Market. II-54 Table 8:Leading Players in the US Antidepressants Ratiopharm Launches Ratio-Paroxetine in Canada . II-54 Market (2004 & 2005(E)): Percentage Breakdown of Value Sales for Forest Labs, GlaxoSmithKline, Apotex Releases Generic Version of Paxil. II-54 Pfizer, Wyeth, Eli Lilly and Others (include corresponding Graphs/Chart) .III-2 Table 9: Leading Players in the US SSRI/SNRI Market (2004 & 2005(E)): Percentage Breakdown of 8. Recent Industry Activity. II-56
Value Sales for Forest Labs, Pfizer, Wyeth, GlaxoSmithKline, Eli Lilly and Others Organon in Marketing Agreement with STADA. II-56 (include corresponding Graphs/Chart) .III-3 Andrx Signs Marketing Agreement with Impax and Teva . II-56 GlaxoSmithKline Collaborates with NeuroSearch . II-56 Lundbeck in Marketing Accord with Janssen-Cilag. II-56 New Drugs Set to Conquer the Market .III-4 Lundbeck Allies with Abbott Laboratories . II-57 Myriad Signs an Agreement with Abbott Laboratories . II-57 Table 10: Leading SSRI/ SNRI Brands in the US Recordati Obtains Marketing Rights from H Lundbeck . II-57 Antidepressants Market (2000-2005(E)): Percentage Breakdown of Sales for Prozac, Paxil, Zoloft, 9. Focus on Select Global Players . II-58
Celexa, Lexapro, Effexor and Others (include corresponding Graphs/Chart) . III-4 Number of SSRI/SNRI Prescriptions Dispensed in Millions (include corresponding Graphs/Chart) . III-5 Advertising Expenditure in US$ Million on Select SSRIs - Celexa (Citalopram), Prozac (Fluoxetine), Effexor XR (Venlafaxine), Zoloft (Sertraline), Organon International, Inc. (USA) . II-60 Paxil (Paroxetine), and Luvox (Fluvoxamine) (include corresponding Graphs/Chart) .III-5 Depression More Common Among Gays .III-5 FDA Inspects Suicidal Tendencies in Kids on 10. Global Market Perspective . II-63
Table 6: World Recent Past, Current & Future Analysis for Generic Drugs Pose Competition to Branded Drugs .III-7 Antidepressants by Geographic Region – USA, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin America Markets Independently Analyzed with Annual Sales Antidepressants Market (2001): Sales in US$ Million Figures in US$ Million for Years 2000 through 2010 for Zoloft, Paxil, Prozac & Sarafem, Celexa, and (include corresponding Graphs/Chart) .II-63 Luvox (include corresponding Graphs/Chart) .III-7 ANTIDEPRESSANTS - A GLOBAL STRATEGIC BUSINESS REPORT 01/06 This Report Is Protected With Digital Watermarks. Copyrights per US & ICC protocols. This Document May Not Be Printed, Copied or Distributed Outside Your Organization in Any Form Without Our Express Written Permission ANTIDEPRESSANTS
MCP-1383
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
Depression Drugs Being Used for Symptoms Other 3. Japan. III-18
US Antidepressants Market: Drugs Approved Frequent Patent Expiries – A Cause of Concern Table 18: CNS Market in Japan (2001): Sales in US$ Patent Expiry of Select Antidepressant Brands Million by Drug Class – Antidepressants, Antiulcerants, Cholesterol Reducers, Broad Antibiotic, Antiarrhythmic, Antihypertensive, Narcotic painkiller, Oral Diabetes, Oral Antihistamine, and Antiseizure (include corresponding Graphs/Chart) .III-19 Table 19: Leading Brands in the Japanese Antidepressants Market (2001 & 2002): Percentage Breakdown of Value Sales for Paxil, Luvox, Depromel, Ludiomil, Toledomin, Toledomin- Jansen, Anafranil, Tetramide, and Others (include corresponding Graphs/Chart) .III-20 Antidepressants Market in Japan – Major Drug Table 14: US Recent Past, Current & Future Analysis for Antidepressants by Product Segment – SSRI, New Generation, TCA and MAOI Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Table 20: Japanese Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 Table 15: US 10-Year Perspective for Antidepressants by (include corresponding Graphs/Chart) .III-22 Product Segment – Percentage Breakdown of Dollar Sales for SSRI, New Generation, TCA and 4. Europe. III-23
MAOI for Years 2000, 2005 & 2010 (include corresponding Graphs/Chart) .III-14 2. Canada . III-15
Table 21: Leading Players in the European Antidepressants Market (2004 & 2005(E)) – Percentage Breakdown of Value Sales for GlaxoSmithKline, Eli Lilly, Lundbeck, Pfizer, Wyeth and Others Increasing Use of Antidepressants among Canadian (include corresponding Graphs/Chart) .III-24 Antidepressants Market - A Recent Past Perspective .III-15 Changes in European Patent Litigation.III-24 Percentage Breakdown of Value Sales by Class – SSRI, TCAs, MOAI, and Others (include corresponding Graphs/Chart) .III-16 Table 22: European Recent Past, Current & Future Analysis for Antidepressants by Geographic Region – France, Germany, UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in Warning Against Antidepressants Use in Under- US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart) .III-25 Table 23: European 10-Year Perspective for Antidepressants by Geographic Region – Percentage Table 17: Canadian Recent Past, Current & Future Breakdown of Dollar Sales for France, Germany, Analysis for Antidepressants: Annual Sales Figures UK, Italy, Spain, and Rest of Europe Markets for in US$ Million for Years 2000 through 2010 Years 2000, 2005 & 2010 (include corresponding (include corresponding Graphs/Chart) .III-17 ANTIDEPRESSANTS - A GLOBAL STRATEGIC BUSINESS REPORT 01/06 This Report Is Protected With Digital Watermarks. Copyrights per US & ICC protocols. This Document May Not Be Printed, Copied or Distributed Outside Your Organization in Any Form Without Our Express Written Permission ANTIDEPRESSANTS
MCP-1383
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
4a. France. III-27
4f. Rest of Europe . III-35
Table 24: French Recent Past, Current & Future Analysis Focus on Select Regional Markets.III-35 for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 Danish People Display Greater Preference for (include corresponding Graphs/Chart) .III-27 4b. Germany . III-28
Table 25: German Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart) .III-28 4c. The United Kingdom. III-29

Table 30: Rest of Europe Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 III-34 (include corresponding Graphs/Chart) .III-36 UK Bans Antidepressant Use in Children (2003) .III-29 2000): Number of Associated Deaths in England and 5. Asia-Pacific . III-37
Wales by Drug Class – TCAs, MAOIs, SSRIs and Others (include corresponding Graphs/Chart) .III-30 A Recent Past Market Perspective .III-37 Antidepressants, a Happy Pill for Sad Scots .III-30 Table 27: UK Recent Past, Current & Future Analysis Table 31: Asia-Pacific Recent Past, Current & for Antidepressants: Annual Sales Figures in Future Analysis for Antidepressants: Annual US$ Million for Years 2000 through 2010 Sales Figures in US$ Million for Years (include corresponding Graphs/Chart) .III-32 2000 through 2010 (include corresponding Graphs/Chart) .III-38 4d. Italy . III-33

America. III-39
Table 28: Italian Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart) .III-33 High Usage of Antidepressants among Chileans.III-39 4e. Spain. III-34
Table 32: Latin America Recent Past, Current & Table 29: Spanish Recent Past, Current & Future Future Analysis for Antidepressants: Annual Analysis for Antidepressants: Annual Sales Figures Sales Figures in US$ Million for Years in US$ Million for Years 2000 through 2010 2000 through 2010 (include corresponding (include corresponding Graphs/Chart) .III-34 ANTIDEPRESSANTS - A GLOBAL STRATEGIC BUSINESS REPORT 01/06 This Report Is Protected With Digital Watermarks. Copyrights per US & ICC protocols. This Document May Not Be Printed, Copied or Distributed Outside Your Organization in Any Form Without Our Express Written Permission ANTIDEPRESSANTS
MCP-1383
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
IV. COMPETITION
Table 52: Nine Months Sales Analysis by Product: Table 33: Half Yearly Sales Analysis: 2004-2005 (H1) 2004-2005 (Nine Months Ended, March) Table 34: Half Yearly Sales Analysis by Segment: Table 53: Annual Sales Analysis: 2003-2004 2004-2005 (H1) (In US$ million). IV-4 Table 35: Quarterly Sales Analysis: 2003-2004 Table 54: Annual Sales Analysis by Product: 2003-2004 (In US$ million) . IV-69 Table 36: Annual Sales Analysis by Segment: 7. Boehringer Ingelheim GmbH (Germany). IV-71 2003-2004 (In US$ million) . IV-4 Table 55: Annual Sales Analysis: 2003-2004 Table 37: Annual Sales Analysis by Geographical Region: 2003-2004 (In US$ million). IV-5 Table 56: Annual Sales Analysis by Product Segment: 2003-2004 (In € million) . IV-71 2. Akzo Nobel NV (The Netherlands). IV-23 Table 57: Annual Sales Analysis by Region: Table 38: First Quarter Sales Analysis: 2003-2004 (In € million) . IV-72 2004-2005 (Q1) (In € million). IV-28 8. Bristol-Myers Squibb Co. (USA) . IV-77 Table 39: First Quarter Sales Analysis by Segment: Table 58: Annual Sales Analysis: 2003-2004 2004-2005 (Q1) (In € million). IV-28 Table 40: Annual Sales Analysis: 2002-2004 Table 59: Annual Sales Analysis by Segment: 2003-2004 (In US$ billion) . IV-79 Table 41: Annual Sales Analysis by Segment: Table 60: Annual Sales Analysis by Geographic 2003-2004 (In € million). IV-28 Region: 2003-2004 (In US$ billion). IV-79 Table 42: Annual Sales Analysis by Region: 9. Cortex Pharmaceuticals, Inc. (USA) . IV-91 2003-2004 (In € million). IV-29 10. Dr. Reddy's Laboratories Ltd. (India). IV-93 Table 61: Annual Sales Analysis: 2003-2005 Organon International, Inc. (USA). IV-36 Table 62: Annual Sales Analysis by Product Segment: 2003-2004 (In INR million). IV-95 Table 43: First Quarter Sales Analysis: Table 63: Annual Sales Analysis by Geographical 2004-2005 (Q1) (In US$ million). IV-44 Region: 2003-2004 (In INR million) . IV-95 Table 44: Annual Sales Analysis: 2003-2004 Table 64: Half Yearly Sales Analysis: Table 45: Quarterly Sales Analysis: 2003-2004 2004-2005 (H1) (In US$ million). IV-99 Table 65: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In US$ million). IV-99 Table 66: Half Yearly Sales Analysis by Product: Table 46: First Quarter Sales Analysis: 2004-2005 (H1) (In US$ million). IV-99 2004-2005 (Q1) (In US$ billion). IV-56 Table 67: Annual Sales Analysis: 2002-2004 Table 47: First Quarter Sales Analysis by Geographic Region: 2004-2005 (Q1) (In US$ billion) . IV-57 Table 68: Annual Sales Analysis by Segment: Table 48: Annual Sales Analysis: 2003-2004 2003-2004 (In US$ million) . IV-100 Table 69: Annual Sales Analysis by Product: Table 49: Annual Sales Analysis by Therapy Area: 2003-2004 (In US$ million) . IV-100 2003-2004 (In US$ billion) . IV-57 Table 70: Annual Sales Analysis by Geographical Table 50: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million). IV-101 Region: 2003-2004 (In US$ billion). IV-57 Table 71: Quarterly Sales Analysis: 2003-2004 Astrazeneca Pharmaceuticals LP (USA). IV-66 Eli Lilly And Company Limited (UK) . IV-107 Table 51: Nine Months Sales Analysis: 2004-2005 (Nine months Ended, March) (In US$ million) . IV-68 Lilly Deutschland GmbH (Germany). IV-108 ANTIDEPRESSANTS - A GLOBAL STRATEGIC BUSINESS REPORT 01/06 This Report Is Protected With Digital Watermarks. Copyrights per US & ICC protocols. This Document May Not Be Printed, Copied or Distributed Outside Your Organization in Any Form Without Our Express Written Permission ANTIDEPRESSANTS
MCP-1383
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
Table 92: First Quarter Sales Analysis by Geographical Table 72: First Quarter Sales Analysis: Region: 2004-2005 (Q1) (In US$ billion) . IV-149 2004-2005 (Q1) (In US$ million). IV-111 Table 93: Annual Sales Analysis: 2003-2004 Table 73: Annual Sales Analysis: 2002-2004 Table 94: Annual Sales Analysis by Segment: Table 74: Quarterly Sales Analysis: 2003-2004 2003-2004 (In US$ billion) . IV-149 Table 95: Annual Sales Analysis by Geographical 13. F. Hoffmann-La Roche Ltd. (Switzerland) . IV-112 Region: 2003-2004 (In US$ billion). IV-150 Table 75: Half Yearly Sales Analysis: Table 96: Annual Sales Analysis by Quarter: 2004-2005 (H1) (In CHF million). IV-113 2003-2004 (In US$ billion) . IV-150 Table 76: Annual Sales Analysis: 2003-2004 19. Janssen-Cilag International NV (Belgium). IV-157 Table 77: Annual Sales Analysis by Division: 21. Meiji Seika Kaisha Ltd. (Japan) . IV-160 2003-2004 (In CHF millions). IV-113 Table 97: Annual Sales Analysis: 2003-2004 14. Forest Laboratories, Inc. (USA). IV-118 Table 78: First Quarter Sales Analysis: Table 98: Annual Sales Analysis by Business 2005-2006 (Q1) (In US$ billion). IV-119 Segment: 2003-2004 (In ¥ million). IV-160 Table 79: Annual Sales Analysis: 2004-2005 Table 99: Annual Sales Analysis: 2003-2004 Table 80: Quarterly Sales Analysis: 2004-2005 Table 100: Annual Sales Analysis by Segment: Table 81: Annual Sales Analysis by Geographical 2003-2004 (In US$ Million). IV-163 Region: 2004-2005 (In US$ billion). IV-120 Table 101: Quarterly Sales Analysis: 2003-2004 Table 82: Quarterly Sales Analysis: 2003-2004 23. Mylan Laboratories, Inc. (USA). IV-165 Table 83: Annual Sales Analysis by Geographical Table 102: First Quarter Sales Analysis: Region: 2003-2004 (In US$ billion). IV-120 2005-2006 (Q1) (In US$ million). IV-166 Forest Pharmaceuticals, Inc. (USA). IV-124 Table 103: Annual Sales Analysis: 2003-2005 Table 84: Half Yearly Sales Analysis: Table 104: Annual Sales Analysis by Business 2004-2005 (H1) (In £ million). IV-126 Segment: 2004-2005 (In US$ million) . IV-166 Table 85: Half Yearly Sales Analysis by Division: Table 105: Annual Sales Analysis by Product: 2004-2005 (H1) (In £ million). IV-126 2004-2005 (In US$ million) . IV-166 Table 86: Annual Sales Analysis: 2003-2004 Table 106: Quarterly Sales Analysis: 2004-2005 Table 87: Annual Sales Analysis by Division: 24. Myriad Genetics, Inc. (USA) . IV-170 2003-2004 (In £ million). IV-126 Table 107: Annual Sales Analysis: 2003-2004 (In US$ million) . IV-171 Glaxo Smithkline Canada, Inc. (Canada). IV-139 Table 108: Annual Sales Analysis by Segment: 2003-2004 (In US$ million) . IV-171 Table 88: Annual Sales Analysis: 2002-2004 Table 89: Annual Sales Analysis by Geographical Table 109: Half Yearly Sales Analysis: Region: 2003-2004 (In DKK billion) . IV-142 2004-2005 (H1) (In US$ billion). IV-178 17. Impax Laboratories, Inc. (USA). IV-144 Table 110: Annual Sales Analysis: 2002-2004 Table 90: First Quarter Sales Analysis: Table 111: Annual Sales Analysis by Division: 2004-2005 (Q1) (In US$ billion). IV-149 2003-2004 (In US$ billion) . IV-179 Table 91: First Quarter Sales Analysis by Segment: Table 112: Annual Sales Analysis by Geographical 2004-2005 (Q1) (In US$ billion). IV-149 Region: 2003-2004 (In US$ billion). IV-179 ANTIDEPRESSANTS - A GLOBAL STRATEGIC BUSINESS REPORT 01/06 This Report Is Protected With Digital Watermarks. Copyrights per US & ICC protocols. This Document May Not Be Printed, Copied or Distributed Outside Your Organization in Any Form Without Our Express Written Permission ANTIDEPRESSANTS
MCP-1383
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
Table 113: Quarterly Sales Analysis: 2003-2004 Table 130: Annual Sales Analysis: 2003-2004 Sandoz Deutschland GmbH (Germany). IV-190 Table 131: Annual Sales Analysis by Region: 2003-2004 (In £ million) . IV-249 28. Orion Corporation (Finland) . IV-195 Table 114: Annual Sales Analysis: 2003-2004 Table 132: First Quarter Sales Analysis: 2004-2005 (Q1) (In € million). IV-255 29. Paddock Laboratories, Inc. (USA) . IV-198 Table 133: Annual Sales Analysis: 2003-2004 30. Par Pharmaceutical, Inc. (USA) . IV-202 Table 115: First Quarter Sales Analysis: Table 134: Annual Sales Analysis by Segment: 2004-2005 (Q1) (In US$ million). IV-202 2003-2004 (In € million) . IV-255 Solvay Pharmaceutical, Inc. (USA) . IV-263 Table 116: Annual Sales Analysis: 2003-2004 (In US$ million) . IV-203 40. STADA Arzneimittel AG (Germany) . IV-265 Table 135: First Quarter Sales Analysis: Table 117: Annual Sales Analysis by Quarter: 2004-2005 (Q1) (In € million). IV-265 2003-2004 (In US$ million) . IV-203 Table 136: First Quarter Sales Analysis by Segment: 2004-2005 (Q1) (In € million). IV-266 Table 118: Half Yearly Sales Analysis: Table 137: Annual Sales Analysis: 2003-2004 2004-2005 (H1) (In US$ billion). IV-207 Table 119: Annual Sales Analysis: 2003-2004 Table 138: Annual Sales Analysis by Segment: 2003-2004 (In € million) . IV-266 Table 120: Annual Sales Analysis by Business 41. Strides Arcolab Limited (India). IV-268 Segment: 2003-2004 (In US$ billion). IV-207 42. Temmler Pharma GmbH & Co. KG (Germany). IV-271 Table 121: Annual Sales Analysis by Geographic 43. Teva Pharmaceutical Industries Ltd. (Israel) . IV-272 Region: 2003-2004 (In US$ billion). IV-207 Table 139: Half Yearly Sales Analysis: Pfizer Australia Pty., Ltd. (Australia) . IV-221 2004-2005 (H1) (In US$ Million). IV-273 Table 140: Half Yearly Sales Analysis by Geographic Region: 2004-2005 (H1) (In US$ Million) . IV-273 Table 141: Half Yearly Sales Analysis by Business 32. Ranbaxy Pharmaceuticals, Inc. (USA). IV-229 Segment: 2004-2005 (H1) (In US$ Million). IV-274 Table 142: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ Million). IV-274 Table 122: Half-Yearly Sales Analysis: Table 143: Annual Sales Analysis by Business 2004-2005 (H1) (In € million). IV-234 Segment: 2003-2004 (In US$ Million) . IV-274 Table 123: Annual Sales Analysis: 2003-2004 44. Watson Pharmaceuticals, Inc. (USA) . IV-279 Table 144: Annual Sales Analysis: 2003-2004 Table 124: Annual Sales Analysis by Segment: 2003-2004 (In € million). IV-235 Table 145: Annual Sales Analysis by Business Segment: 2003-2004 (In US$ million). IV-280 Table 125: Annual Sales Analysis by Geographical Region: 2003-2004 (In € million). IV-235 Table 146: Half yearly Sales Analysis: 2004-2005 (H1) (In US$ million). IV-285 Table 147: Half Yearly Sales Analysis by Segment: Table 126: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million). IV-285 2004-2005 (H1) (In € million). IV-242 Table 148: Annual Sales Analysis: 2003-2004 Table 127: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In € million). IV-242 Table 149: Annual Sales Analysis by Segment: Table 128: Half Yearly Sales Analysis by Product: 2003-2004 (In US$ million) . IV-285 2004-2005 (H1) (In € million). IV-242 Table 150: Annual Sales Analysis by Region: Table 129: Annual Sales Analysis: 2003-2004 2003-2004 (In US$ million) . IV-285 Wyeth Australia Pty., Ltd. (Australia). IV-290 ANTIDEPRESSANTS - A GLOBAL STRATEGIC BUSINESS REPORT 01/06 This Report Is Protected With Digital Watermarks. Copyrights per US & ICC protocols. This Document May Not Be Printed, Copied or Distributed Outside Your Organization in Any Form Without Our Express Written Permission

Source: http://www.oic.co.kr/files/gia10043.pdf

Jpcooke_resume_srprojectmanager

J. Patrick Cooke // Sr. Project Manager Professional Experience May 2013 – September 2013 // Blast Radius / Wunderman World Health, New York, NY As a Sr. PM at Blast Radius I was responsible for the day-to-day management activities on the entire Novartis Gas-X account, as well as portions of the Novartis Prevacid account. Including but not limited to financial forecasting and budgeting

Capitolo decimo

Capitolo 10° PROFEZIA La manciata di giorni, notti, ore e minuti di fine d’anno passarono ovattati senza fare rumore; poi, allo stesso modo, in alleanza col silenzio, arrivò il mattino del trentun dicembre: il giorno di Profezia. Un giorno importante che una volta in scena viziò il silenzio e prese a fare cigolare il passaggio delle ore e dei minuti togliendo l'ovatta ai rumori e r

Copyright © 2010-2014 Medical Articles